CSIMarket Company Name, Ticker, Customers, else..
 
Aim Immunotech Inc   (NYSEAMER: AIM)
 

Aim Immunotech Inc's Suppliers Performance

AIM's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
AIM Costs vs Sales of Suppliers Growth Aim Immunotech Inc's cost of sales deteriorated by -60 % year on year, relative to one quarter ago cost of sales fell by -90 % in Q1.

• More on AIM Suppliers



Aim Immunotech Inc's cost of sales deteriorated by -60 % year on year, compare to one quarter ago cost of sales fell by -90 % in Q1.

• More on AIM Suppliers




Aim Immunotech Inc's Comment on Supply Chain


The company faces risks related to suppliers, sourcing, and raw materials, including the potential inability to manufacture Ampligen due to shortages of raw materials or services. Commercial sales of Alferon N Injection were halted because of a lack of finished goods inventory. In the United States, there are few organizations capable of performing final manufacturing steps such as formulation, fill, finish, and packing for Ampligen and Alferon N Injection. The company has limited manufacturing experience with these products and may not achieve profitability unless it can produce them in commercial quantities at acceptable costs. There is no assurance that small-scale investigational manufacturing will successfully transition to large-scale commercial production.

Aim Immunotech Inc's Comment on Supply Chain


The company faces risks related to suppliers, sourcing, and raw materials, including the potential inability to manufacture Ampligen due to shortages of raw materials or services. Commercial sales of Alferon N Injection were halted because of a lack of finished goods inventory. In the United States, there are few organizations capable of performing final manufacturing steps such as formulation, fill, finish, and packing for Ampligen and Alferon N Injection. The company has limited manufacturing experience with these products and may not achieve profitability unless it can produce them in commercial quantities at acceptable costs. There is no assurance that small-scale investigational manufacturing will successfully transition to large-scale commercial production.







AIM's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Aim Immunotech Inc 0.89 0.09 -13.28 21
SUBTOTAL 0.00 0.00 0.00 -


Sources: Aim Immunotech Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Aim Immunotech Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.